Phase II study of ABV with increased dose of adriamycin (ADM) and deleted DTIC followed by adjuvant involved-field radiotherapy (ABV/IFRT) to residual or initial bulky tumor for the previously untreated patients with advanced Hodgkin's disease (stage IB, IIB, III, IV or bulky). (JCOG9705)

Phase II study of ABV with increased dose of adriamycin (ADM) and deleted DTIC followed by adjuvant involved-field radiotherapy (ABV/IFRT) to residual or initial bulky tumor for the previously untreated patients with advanced Hodgkin's disease (stage IB, IIB, III, IV or bulky). (JCOG9705) - Phase II study of ABV with increased dose of adriamycin (ADM) and deleted DTIC followed by adjuvant involved-field radiotherapy (ABV/IFRT) to residual or initial bulky tumor for the previously untreated patients with advanced Hodgkin's disease (stage IB, IIB, III, IV or bulky). (JCOG9705)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000068

Enrollment

108

Registered

2005-08-18

Start date

1998-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

previouly untreated advanced stage Hodgkin lymphoma (stage IB, IIB, III, IV, or bulky)

Interventions

polychemotherapy, raiotheraoy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Biopsy-proven Hodgkin lymphoma (2) Clinical stage IB, IIB, III, IV or bulky IA, IIA (3) PS 0-3 (ECOG) (3) No severe organ dysfunction (4) Age: 15<=, < 70 (5) Previously untreated (6) With evaluable lesions (7) Written informed consent

Exclusion criteria

Exclusion criteria: 1. insulin dependent diabetes mellitus 2. severe comorbidity (e.g. severe infectious disease, heart failure, pulmonary disease, hepatic failure, liver cirrhosis, acute/chronic hepatitis, renal failure, active tuberculosis) 3. other active neoplasms except insitu carcinoma of uterus and basal cell carcinoma of skin) 4. psychological disease 5. severe cardiac disease that may deteriorate by doxorubicin. Past history of myocardial infarction, heart failure, renal failure. Past history of angina pectoris 3 months before entry. 6. Pregnant or feeding women 7. CNS involvement by lymphoma 8. Positive for HBs-Ag, HCV-Ab, HIV or HTLV-1

Design outcomes

Primary

Measure	Time frame
complete response rate (%CR+%CRu)	—

Secondary

Measure	Time frame
overall survival, progression-free survival, CR duration, toxicity	—

Countries

Japan

Contacts

Public ContactMichinori Ogura, MD, PhD

JCOG9705 Coordinating Office Department of Hematology, Nagoya Daini Red Cross Hospital

JCOG_sir@ml.jcog.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026